RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
27.39
-0.23 (-0.83%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close27.62
Open27.25
Bid0.00 x 0
Ask0.00 x 0
Day's Range27.25 - 27.40
52 Week Range27.25 - 34.52
Volume1,398,399
Avg. Volume2,035,375
Market Cap187.018B
Beta0.53
PE Ratio (TTM)20.93
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.08 (3.87%)
Ex-Dividend Date2018-03-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Label Expansion May Boost Opdivo’s Revenues in 2018
    Market Realist8 hours ago

    Label Expansion May Boost Opdivo’s Revenues in 2018

    Bristol-Myers Squibbs (BMY) is anticipating key data readouts from multiple phase 3 trials evaluating Opdivo in indications such as gastric cancer, head and neck cancer, small cell lung cancer, and hepatocellular carcinoma, by the end of 2019. On April 18, Bristol-Myers Squibb announced that the FDA had granted priority review for a supplemental biologics application (or sBLA) seeking approval for Opdivo in the third-line small cell lung cancer (or SCLC) indication. The Prescription Drug User Fee Act (or PDUFA) date for this application has been set for August 16.

  • Opdivo May Witness Decline in This Target Patient Population
    Market Realist9 hours ago

    Opdivo May Witness Decline in This Target Patient Population

    At end of Q1 2018, Bristol-Myers Squibb’s (BMY) Opdivo earned 40% of its revenues in the US market from the lung cancer indication, while the remaining US market revenues were attributable to demand for the drug in other tumor types. By the end of Q1 2018, the drug had managed to maintain its market share in the second-line lung cancer segment in the US.

  • Financial Times18 hours ago

    [$$] Stocks to watch: Kingfisher, AstraZeneca, Imperial Brands, Roche

    distressed debt specialist Hilco Capital for a nominal sum. also gained after Wesfarmers of Australia, which trades under the Bunnings banner, warned that its exit from the UK would generate a £200m loss. “Critically, Homebase will miss the considerable buying muscle of Bunnings in Asia, and we would expect less aggressive pricing on seasonal products,” said Jefferies, which saw B&Q benefiting from reduced capital expenditure requirements and a “sharply improved” outlook for margins.

  • The Performance of Roche’s Tarceva, Actemra, and Other Drugs
    Market Realist2 days ago

    The Performance of Roche’s Tarceva, Actemra, and Other Drugs

    Roche’s (RHHBY) Tarceva generated revenues of 141 million Swiss francs in the first quarter compared to 211 million Swiss francs in the first quarter of 2017, which reflected an ~32% YoY (year-over-year) CER (constant exchange rate) decline and a 31% sequential decline.

  • InvestorPlace2 days ago

    3 Top Biosimilars that Will Lift Pfizer Inc. Stock Even More

    A month ago, Pfizer Inc. (NYSE:PFE) felt the sting of a somewhat surprising disappointment. Its biosimilar version of Herceptin, the popular breast cancer drug from Roche Holding AG (OTCMKTS:RHHBY), was rejected by the FDA.Biosimilar drugs are nearly-identical copies of a competitor’s product. It was a blow not just because Herceptin generated sales of more than $7 billion last year, but because it put the viability of Pfizer’s entire biosimilar program into question.

  • An Update on the Performance of Roche’s Immunology Portfolio
    Market Realist2 days ago

    An Update on the Performance of Roche’s Immunology Portfolio

    Roche’s (RHHBY) Xolair generated revenues of 442 million Swiss francs in the first quarter compared to 437 million Swiss francs in the first quarter of 2017, which reflected ~1% YoY (year-over-year) growth and ~3% growth sequentially. In the US market, Roche commercializes Xolair while Novartis commercializes it outside the US market. In the first quarter, Novartis (NVS) reported revenues of $255 million from the sales of Xolair, which reflected ~14% YoY growth.

  • Reuters2 days ago

    Vontobel to buy private bank from Raiffeisen for $700 million

    Swiss private bank and asset manager Vontobel (VONN.S) is buying private bank Notenstein La Roche from Swiss cooperative bank Raiffeisen [RFSHW.UL] for 700 million Swiss francs ($705 million), the two parties said on Thursday. "Notenstein La Roche perfectly complements the strong organic growth we have achieved in wealth management over a number of years," Vontobel Chief Executive Zeno Staub said in a statement.

  • Roche’s Hemlibra Could Drive Long-Term Growth
    Market Realist3 days ago

    Roche’s Hemlibra Could Drive Long-Term Growth

    In the first quarter, Roche’s (RHHBY) Hemlibra generated revenues of 23 million Swiss francs, which included revenues of 18 million Swiss francs from the US market and 5 million Swiss francs from the European market.

  • Tecentriq Could Be Roche’s Long-Term Growth Driver
    Market Realist3 days ago

    Tecentriq Could Be Roche’s Long-Term Growth Driver

    Roche’s (RHHBY) Tecentriq (atezolizumab), a PD-L1 blocker is approved for use in the treatment of individuals with metastatic urothelial carcinoma in patients. These patients would not be eligible candidates for cisplatin-containing chemotherapy, or showed disease progression after treatment with platinum-containing chemotherapy.

  • How Tecentriq Is Positioned after Q1 2018
    Market Realist3 days ago

    How Tecentriq Is Positioned after Q1 2018

    In the first quarter, Roche’s (RHHBY) Tecentriq generated revenues of 139 million Swiss francs compared to 113 million Swiss francs in the first quarter of 2017, which reflected ~29% year-over-year (or YoY) CER (constant exchange rate) growth. In the US market, Tecentriq witnessed ~5% YoY growth in the first quarter.

  • Roche’s Ocrevus Witnessed Solid Growth in Q1 2018
    Market Realist4 days ago

    Roche’s Ocrevus Witnessed Solid Growth in Q1 2018

    In the first quarter, Roche’s (RHHBY) Ocrevus generated revenues of 479 million Swiss francs compared to 369 million Swiss francs in the fourth quarter of 2017, which reflected ~30% sequential growth.

  • Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018
    Market Realist4 days ago

    Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018

    Roche’s (RHHBY) MabThera/Rituxan reported revenues of 1.7 billion Swiss francs in the first quarter compared to 1.9 billion Swiss francs in the first quarter of 2017, which reflected a decline of ~8% YoY (year-over-year) on constant exchange rate basis.

  • Should You Buy Roche Holding AG (VTX:ROG) At This PE Ratio?
    Simply Wall St.4 days ago

    Should You Buy Roche Holding AG (VTX:ROG) At This PE Ratio?

    Roche Holding AG (SWX:ROG) is currently trading at a trailing P/E of 22.2x, which is lower than the industry average of 24.8x. While ROG might seem like an attractive stockRead More...

  • Roche Proves Again Why It Will Likely Rout Shire's Hemophilia Business
    Investor's Business Daily4 days ago

    Roche Proves Again Why It Will Likely Rout Shire's Hemophilia Business

    Roche jumped early Monday on unsurprisingly strong data for its hemophilia treatment, Hemlibra — prodding shares of Shire to slip.

  • Roche (RHHBY) Announces Positive Data on Hemophilia Drug
    Zacks4 days ago

    Roche (RHHBY) Announces Positive Data on Hemophilia Drug

    Roche (RHHBY) announces positive data from two phase III studies on hemophilia drug Hemlibra which has further strengthened its hemophilia portfolio.

  • How Roche’s Herceptin and Kadcyla Performed in Q1 2018
    Market Realist5 days ago

    How Roche’s Herceptin and Kadcyla Performed in Q1 2018

    Roche’s (RHHBY) Herceptin reported revenues of 1.77 billion Swiss francs in the first quarter compared to 1.76 billion Swiss francs in the first quarter of 2017, which reflected ~2.0% YoY (year-over-year) growth at constant exchange rates. In the fourth quarter of 2017, Herceptin reported revenues of 1.78 billion Swiss francs, which reflects a flat revenue trend compared to the first quarter.

  • The Performance of Roche’s Diagnostics Division in Q1 2018
    Market Realist5 days ago

    The Performance of Roche’s Diagnostics Division in Q1 2018

    Roche’s (RHHBY) Diagnostics division comprises tissue diagnostics, molecular diagnostics, diabetes care, and centralized and point-of-care solutions. Roche’s Diagnostics division grew 5.0% year-over-year to reach ~2.9 billion Swiss francs.

  • A Look into Roche Holding’s Performance in Q1 2018
    Market Realist5 days ago

    A Look into Roche Holding’s Performance in Q1 2018

    In the first quarter, Roche Holding (RHHBY) reported revenues of ~13.6 billion Swiss francs compared to ~12.9 billion Swiss francs in the first quarter of 2017, which reflected ~5.0% growth on a YoY (year-over-year) basis.

  • Reuters5 days ago

    Roche drug dramatically reduces bleeds in key haemophilia tests

    Roche's new haemophilia drug Hemlibra dramatically reduced bleeding in a broad population of haemophilia patients, results from two clinical trials showed on Monday, setting it up to take a dominant market position. Hemlibra cut by 96 percent the incidence of treated bleeds in haemophilia A patients who did not get preventive treatment, and compared with patients who did get preventive treatment in the form of clotting factors it reduced them by 68 percent. The positive results from the two trials known as HAVEN 3 and 4 included so-called non-inhibitor patients.

  • Exelixis Is Focused on Management of the Cabozantinib Franchise
    Market Realist8 days ago

    Exelixis Is Focused on Management of the Cabozantinib Franchise

    Exelixis (EXEL) is focused on the label expansion and life cycle management of the cabozantinib franchise in collaboration with Bristol-Myers Squibb (BMY) and Roche Holdings (RHHBY). The above diagram shows the rationale for studying cabozantinib in combination with immunotherapy in multiple cancer indications. Exelixis is currently evaluating the safety and preliminary activity, in terms of objective response rate and progression-free survival, of a combination of cabozantinib with nivolumab and a combination of cabozantinib with nivolumab and ipilimumab in advanced hepatocellular carcinoma (or HCC) indications in an ongoing Phase 2 trial.

  • Roche Tecentriq Combo Achieves Longer Overall Survival Rate
    Zacks9 days ago

    Roche Tecentriq Combo Achieves Longer Overall Survival Rate

    Roche's (RHHBY) immuno-oncology drug, Tecentriq, in combination with Avastin and chemotherapies leads to significantly longer overall survival rates in treatment-naive NSCLC patients.

  • Why Exelixis Stock Fell Last Week
    Market Realist9 days ago

    Why Exelixis Stock Fell Last Week

    On May 11, Exelixis’s (EXEL) closing price was $19.55, almost 12.9% lower than its closing price on May 4. This fall was mainly attributable to unfavorable results released from its Phase 3 IMblaze370 study comparing a combination regimen of Cotellic (cobimetinib) with Roche Holdings’ (RHHBY) Tecentriq (atezolizumab) compared to Bayer’s Stivarga in locally advanced or metastatic colorectal cancer indications. Exelixis and Roche Holdings’ investigational combination regimen failed to demonstrate a statistically significant improvement in the primary end point of overall survival compared to Stivarga in difficult-to-treat patients who had witnessed disease progression or had been unable to tolerate at least two chemotherapy treatments.

  • Reuters9 days ago

    Roche immunotherapy combination increases lung cancer survival-study

    Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday. The Phase III study involved 800 people with non-squamous non-small cell lung cancer (NSCLC) whose cancer had spread but who had not yet received chemotherapy.

  • The Wall Street Journal9 days ago

    [$$] No Harm in Reducing Use of Roche Drug for Breast Cancer, Study Says

    The study, funded by the U.K. National Institute for Health Research, was conducted on more than 4,000 women in the early stages of an aggressive type of breast cancer known as HER2-positive. Herceptin, which generated about $7 billion in global sales for Roche last year, has vastly improved treatment for HER2-positive breast cancer since it hit the market in 1998, particularly when used to prevent disease recurrence after breast surgery. In the U.S., the drug costs $76,700 for 12 months of treatment.

  • Study Finds More Isn't Better for Roche Breast Cancer Drug
    Bloomberg9 days ago

    Study Finds More Isn't Better for Roche Breast Cancer Drug

    For more than a decade, women with a dangerous form of breast cancer have relied on Roche Holding AG’s blockbuster drug Herceptin, taking the $76,700-a-year medicine for 12 months to fight off the disease. According to research released Wednesday, women taking Herceptin for six months were just as likely to be free of cancer four years later as those who used the drug for a year, the current standard of care recommended by the U.S. Food and Drug Administration and Roche. “Our field is maturing,” said Bruce Johnson, chief clinical research officer at the Dana-Farber Cancer Institute in Boston and president of the American Society of Clinical Oncology, or ASCO.